youtube_live
Q3 2026 earnings • released • EPS beat +2.73% • Revenue beat +1.84%
See resultschevron_right
EXEL:NASDAQ
Exelixis Inc
$72.26
arrow_upward
+3.03%(+2.12) 1D
Nov 3, 9:48:06 AM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EXEL...
Open
$70.11
High
$72.20
Low
$70.11
Mkt. cap
17.59B
Avg. vol.
2.37M
Volume
93.70K
P/E ratio
21.57
52-wk high
$72.20
52-wk low
$36.00
EPS
$3.34
Beta
0.45
Shares outstanding
244.01M
No. of employees
1K
Open
$70.11
High
$72.20
Low
$70.11
Mkt. cap
17.59B
Avg. vol.
2.37M
Volume
93.70K
P/E ratio
21.57
52-wk high
$72.20
52-wk low
$36.00
EPS
$3.34
Beta
0.45
Shares outstanding
244.01M
No. of employees
1K
News stories
From web sources and news partners
Benzinga
·
1 day ago
Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter
Yahoo Finance
·
3 days ago
Exelixis (EXEL) Beats Q3 Estimates, Is The Stock Fully Priced?
Profile
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
About Exelixis Inc
CEOMichael M. Morrissey
Employees1.08K
FoundedNov 15, 1994
HeadquartersAlameda, California, United States
SectorBiotechnology
Websiteexelixis.com